Loading stock data…
ACRS
$5.09+0.21 (+4.30%)
Pre-Market$5.29+0.20 (+3.88%)· Last close May 13
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aclaris Therapeutics, Inc. in the Healthcare sector is trading at $5.09. Wall Street consensus targets $9.67 (9 analysts), implying a +89.9% move over the next 12 months. The stock is currently near its 52-week high of $5.12, remaining 75.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +89.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$5.09
Potential Downside
0%
Whystock Fair Value$5.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$550.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.98%
Volume
Today's trading volume
2.24M
Recent News
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Aclaris...
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus
Aclaris Therapeutics (NASDAQ:ACRS) provided a clinical program update on Tuesday, highlighting full top-line results from its phase I-A single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ATI-052 and outlining plans to advance oral candidate ATI-2138 into a phase IIb program in li
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming
Aclaris Therapeutics (NASDAQ:ACRS) used an H.C. Wainwright inflammatory skin diseases conference fireside chat to outline development plans and differentiation points for its lead biologic candidate, ATI-052, and to provide updates on its small-molecule pipeline. ATI-052: bispecific approach and ea